Skip to main content

Table 2 Comparison of clinical manifestations of patients who underwent VATSa or radiation

From: Complete remission of metastatic osteosarcoma using combined modality therapy: a retrospective analysis of unselected patients in China

Items VATS (N = 42) Radiotherapy (N = 79) Combination (N = 6)
Number of pulmonary nodules /person
  ≤ 5 nodules 41 (97.6%) 55 (69.6%) 4 (66.7%)
  > 5 nodules 1 (2.4%) 24 (30.4%) 2 (33.3%)
Lung metastasis
 Monolateral 33 (78.6%) 11 (13.9%) 4 (66.7%)
 Bilateral 9 (21.4%) 68 (86.1%) 2 (33.3%)
Dmaxb for pulmonary nodule/nodules
 3–5 mm 3 (7.1%) 15 (19.0%) 0 (0.0%)
 5–10 mm 6 (14.3%) 22 (27.8%) 1 (16.7%)
 10–20 mm 24 (57.1%) 25 (31.6%) 1 (16.7%)
  > 20 mm 9 (21.4%) 17 (21.5%) 4 (66.7%)
Systematic treatment during local therapy of pulmonary noduesc
 MAPI first-line chemotherapy 14 (33.3%) 40 (50.6%) 2 (33.3%)
 IE second-line chemotherapy 24 (57.1%) 25 (31.6%) 4 (66.7%)
 Targeted therapy 2 (4.8%) 11 (13.9%) 0 (0.0%)
 Combination of TKIS and IE chemo 2 (4.8%) 4 (5.1%) 0 (0.0%)
 None 0 (0.0%) 1 (1.3%) 0 (0.0%)
  1. aVATS Video-assisted thoracoscopic surgery
  2. bPatients were classified into four groups based on nodule maximal diameter: 1) 3 mm–5 mm; 2) 5 mm–10 mm; 3) 10 mm–20 mm; 4) > 20 mm
  3. cAt the Musculoskeletal Tumor Center of Peking University People’s Hospital and Peking University Shougang Hospital, a chemo-protocol that includes high-dose methotrexate, cisplatin, doxorubicin, and ifosfamide (MAPI) is used as first-line chemotherapy (seen in appendix Fig. 1); ifosfamide and etoposide (IE) as second-line systematic therapy; anti-angiogenesis tyrosine kinase inhibitors (TKIs) such as apatinib, anlotinib, cabozantinib, and regorafenib as third-line therapy; and the combination of TKIs and IE chemotherapy as fourth-line therapy